Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have agreed to take part and have signed a consent form
• Adults aged 18 to 75 years old (male or female)
• People diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that has been confirmed by a lab test, and cannot be removed by surgery or cured by radiation — either at an advanced local stage (stage IIIB or IIIC) or spread to other parts of the body (stage IV)
• People whose lung cancer has not yet been treated with any systemic (whole-body) anti-cancer therapy
• People whose cancer has specific gene changes known as EGFR exon 19 deletion or L858R mutation, and also tests positive for a protein called MET
• People who are able to provide at least 6 samples of tumor tissue for testing
• People with a physical fitness score of 0 or 1 on a standard scale used by doctors to measure how well a person can carry out daily activities (ECOG scale)
• People who have at least one measurable area of cancer, as assessed using standard imaging guidelines
• People whose life expectancy is at least 12 weeks
• People whose bone marrow, liver, kidneys, and other organs are functioning adequately
• People of childbearing potential (male or female) who agree to use effective contraception from signing the consent form until 6 months after the last dose, and female participants must not be breastfeeding during this time, and male participants must not donate sperm during this period

Who may not be able to join:

• People who have cancer that has spread to the membranes around the brain, is pressing on the spinal cord, or have active brain metastases
• People who have previously received a type of cancer treatment called an ADC (antibody-drug conjugate) or a MET inhibitor
• People who have ongoing severe nausea or vomiting, chronic gut problems, difficulty swallowing, or who have had major bowel surgery that could affect how oral medications are absorbed
• People with cancer-related pain that cannot be adequately controlled
• People who have taken part in another clinical trial or had major surgery within 4 weeks before starting this trial
• People who have received a live vaccine within 28 days before starting the trial, or who plan to receive one during the study
• People with serious heart or blood vessel conditions that are not well controlled
• People with significant fluid build-up in body cavities that cannot be controlled (confirm with trial site)
• People with serious lung conditions, such as active tuberculosis, a lung inflammation condition called interstitial lung disease that requires treatment, or radiation-related lung inflammation
• People who still have side effects from previous cancer treatment that have not recovered to a mild or resolved level
• People with ongoing moderate-to-severe nerve problems affecting sensation or movement (grade 2 or higher)
• People who have had an active infection requiring intravenous (IV) antibiotics within 7 days before starting the trial
• People who test positive for HIV or have a history of AIDS
• People with active hepatitis B or hepatitis C infection
• People who have been taking corticosteroid medicines (such as prednisone) at doses above 10 mg per day, or other immune-suppressing medicines, within 2 weeks before joining the trial
• People who have had another type of cancer within the 5 years before signing the consent form
• People with a known allergy or sensitivity to the study drugs (RC108 or Furmonertinib) or similar medicines
• People who, in the investigator's assessment, are unlikely to be able to follow the study procedures reliably

Important: Always verify eligibility with the trial site directly before applying.